Evidence Hub

Integrated microbiome and metabolome analysis reveals a novel interplay between gut microbiota and metabolites in differentiated thyroid carcinoma

Xue Jiang, Qian Liu, Dongkun Xu, H. Pang, Yu-Hong Shi

BMC Microbiology, 2025

90 participants · 7 citations

Abstract

Differentiated Thyroid carcinoma (DTC) is the most prevalent endocrine malignancy. The identification of novel biomarkers for thyroid carcinoma is essential for enhancing our understanding of the molecular mechanisms underlying DTC development. Notably, gut microorganisms and their metabolites play a role in the development of DTC, although their influence is modulated by the host’s genetic background and environmental factors. Our study aimed to identify and classify gut microbiota and metabolites associated with DTC. 90 patients with a confirmed diagnosis of DTC and 33 healthy volunteers donated stool samples for our analysis. To examine the gut microbiota, we utilized 16 S rRNA gene sequencing, a technique that allows for the identification and classification of microorganisms. Additionally, we employed liquid chromatography-mass spectrometry (LC-MS) to investigate the alterations in metabolites present in thyroid carcinoma patients compared to healthy individuals. The Venn diagram visualized the distribution of bacterial species, with 926 species shared by both groups and 12,225 species unique to DTC patients. Notably, the gut microbiota of DTC patients exhibited higher species richness and diversity compared to healthy individuals. LDA Effect Size (LEfSe) analysis identified Faecalibacterium and Prevotella_9 as more abundant in healthy individuals, while Oscillospiraceae, Subdoligranulum, and Actinobacteriota were significantly more prevalent in DTC patients. We…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free